DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for peeling skin syndrome 5 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePeeling skin syndrome 5 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for peeling skin syndrome 5 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Peeling skin syndrome 5 (acral peeling skin syndrome) is a rare autosomal recessive disorder caused by mutations in the TGM5 gene, which encodes transglutaminase-5, a protein needed for structural integrity of the outermost epidermal layers. In a 2015 study of five patients, three novel TGM5 mutations were identified: c.1001+2_1001+3del, c.1171G>A, and c.1498C>T. Pathogenicity was confirmed through a transglutaminase activity assay, reverse-transcribed PCR analysis of alternative splicing, and database and in silico prediction tools. The majority of patients with this condition originate from Europe and carry a p.(Gly113Cys) mutation in TGM5.
No abstract in this set reports any drug treatment for peeling skin syndrome 5. The remaining abstracts discuss chemical peels as cosmetic and dermatological procedures for photoaging, acne, pigmentation disorders, and scarring, using agents such as glycolic acid and trichloroacetic acid. One 2000 study of more than 3100 patients reported excellent cosmetic results for nonfacial skin with a 70% glycolic acid gel augmented with 40% TCA, neutralised with sodium bicarbonate, with minimal complications. A 2012 review notes that complications of chemical peels range from minor irritation and uneven pigmentation to permanent scarring, and are more likely with darker skin types, certain agents, and sun exposure; in very rare cases complications can be life-threatening.
There is no evidence that chemical peels have been tested or are indicated for peeling skin syndrome 5. The condition is genetic, not acquired, and the abstracts provide no data on any pharmacological intervention. What is missing is any clinical trial, any drug repurposing study, any patient stratification by TGM5 mutation type, and any funding for research into treatments for this specific disorder.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Cutaneous and Aesthetic Surgery · 2012 · 89 citations · open access
Complications of medium depth and deep chemical peels
AbstractSuperficial and medium depth peels are dynamic tools when used as part of office procedures for treatment of acne, pigmentation disorders, and photo-aging. Results and complications are generally related to the depth of wounding, with deeper peels providing more marked results and higher incidence of complications. Complications are also more likely with darker skin types, certain peeling agents, and sun exposure. They can range from minor irritations, uneven pigmentation to permanent scarring. In very rare cases, complications can be life-threatening.
Chemical Peel of Nonfacial Skin Using Glycolic Acid Gel Augmented with TCA and Neutralized Based on Visual Staging
AbstractBACKGROUND: Until recently, standard techniques for laser or chemical peeling have not always provided consistent results when applied to the nonfacial skin. OBJECTIVE: The author describes a more controlled chemical peel technique for nonfacial skin using 70% glycolic acid gel combined with 40% trichloroacetic acid (TCA). The method has given consistently good results on the skin of the neck, chest, arms, hands, back, and other nonfacial skin. METHODS: More than 3100 patients were given skin peels of the neck, chest, and other areas of the body as indicated. Seventy percent glycolic acid gel was applied to the areas to be peeled, then immediately augmented with 40% TCA. Each area was carefully monitored for the end point and then neutralized with copious amounts of 10% sodium bicarbonate solution. The end point was determined by visual observation using a six-stage classification to determine the degree of peeling. RESULTS: Clinical results were excellent, with smoother skin texture, decreased wrinkling and striae, and fading of lentigines and other pigmentary abnormalities. There was excellent blending into peeled facial skin and into adjacent areas of nonpeeled skin. Complications were minimal. CONCLUSION: This technique can provide the benefits of skin peeling to nonfacial skin with excellent cosmetic results and minimal complications.
Novel <scp>TGM</scp>5 mutations in acral peeling skin syndrome
AbstractAcral peeling skin syndrome (APSS, MIM #609796) is a rare autosomal recessive disorder characterized by superficial exfoliation and blistering of the volar and dorsal aspects of hands and feet. The level of separation is at the junction of the stratum granulosum and stratum corneum. APSS is caused by mutations in the TGM5 gene encoding transglutaminase-5, which is important for structural integrity of the outermost epidermal layers. The majority of patients originate from Europe and carry a p.(Gly113Cys) mutation in TGM5. In this study, we report both European and non-European families carrying other mutations in the TGM5 gene. In 5 patients, we found 3 novel mutations: c.1001+2_1001+3del, c.1171G>A and c.1498C>T. To confirm their pathogenicity, we performed functional analyses with a transglutaminase activity assay, determined alternative splicing by reverse-transcribed PCR analysis and used databases and in silico prediction tools.
AbstractChemical peels belong to a group of cutaneous resurfacing procedures that are used in the treatment of photoageing, inflammatory dermatoses, epidermal proliferations, pigmentary disorders and scarring. This review describes best current practice, highlights recent advances in chemical peel technology and discusses the recommended uses for different peel types. It also presents the results of a survey of the chemical peeling practices of 30 Australian dermatologists.
International Journal of Dermatology and Venereology · 2023 · 0 citations · open access
Expert Consensus on the Clinical Application of Chemical Peels in China (2022) #
AbstractChemical peels are widely used to treat various skin diseases and photoaging. Their rational, effective, and safe use has become an important issue in clinical practice. To standardize the clinical use of chemical peels, a group of experts developed this consensus based on the latest research and discussions. This consensus provides specific guidance to clinicians on chemical peels with respect to their classification, peeling agents, mechanisms, indications, contraindications, peeling techniques, and complications.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
